Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Generic Pharmaceuticals Regulation Experts: Healthcare Consultants(?)

Council Members in this Study Group: 27

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Eric Gruff, PhD MBA, Principal, E4 ConsultingEric Gruff, PhD MBA
Principal
E4 Consulting

Eric Gruff, PhD, MBA, BS, is the Founder of E4 Consulting, which specializes in pharmaceutical development, regulatory affairs, and project and portfolio management. Dr. Gruff has over 16 years of experience in the pharmaceutical and biotech sector, including leadership roles at Pfizer, Agouron Pharmaceuticals,...

David Zimmerman, PharmD
President/Owner
Doctors of Pharmacy, Inc.

David Zimmerman, PharmD, FASCP, is the President and an Independent Consultant of Doctors of Pharmacy, Inc. Dr. Zimmerman formerly served as the Director of Clinical Affairs at Employee Health Insurance Management, a pharmacy benefit manager. He has over 30 years of experience, specializing in pharmacy...

Aemad Aslam, MBA
President
MindPharma

Aemad Aslam, BPharm, MBA, RPh, is the President of MindPharma, a pharmacy and retail strategy consulting group. Most recently, he has consulted with a PBM, Prime Therapeutics, in Texas, a subsidiary of Blue Cross Blue Shield. He also has served as an Executive Team Leader for Pharmacy at the Target...

Evan Siegel, MPhil, PhD
President and Chief Executive Officer
Ground Zero Pharmaceuticals, Inc.

Evan Siegel, MPhil, PhD, is the President and Chief Executive Officer at the Ground Zero Pharmaceuticals, Inc., a regulatory affairs and product development consulting firm in California. He provides services in the strategic, regulatory, preclinical, clinical CMC and compliance areas for firms developing...

Joseph Bertino, Pharm.D., Independent Consultant, Bertino ConsultingJoseph Bertino, Pharm.D.
Independent Consultant
Bertino Consulting

Joseph Bertino, PharmD, is an Associate Professor of Pharmacology at Columbia University College of Physicians and Surgeons in New York. Through Bertino Consulting, he consults to the pharmaceutical industry in areas of infectious diseases, drug metabolism, and clinical pharmacology. Dr. Bertino's research...

Jim Farley, President, Cardinal Consulting and TrainingJim Farley
President
Cardinal Consulting and Training

Jim Farley is an Independent Consultant and Owner of Cardinal Consulting and Training. Formerly, Mr. Farley served as the Director of the Science Branch of Philadelphia District FDA. He has over 30 years of experience in pharmaceutical and pharmaceutical packaging industries with extensive experience...

Nailesh Bhatt, Managing Director, Proximare, Inc.Nailesh Bhatt
Managing Director
Proximare, Inc.

Nailesh Bhatt is the Managing Director of Proximare, Inc., a leading strategy consulting firm that exclusively serves the pharmaceutical industry with offices in New Jersey and India. In this role, Mr. Bhatt works with senior pharmaceutical executives to develop and implement growth strategies for R&D,...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Link to Pancreatitis is Bound to Negatively Impact Byetta Sales | 08-21-2008
Author: Eric Gruff, PhD MBA, Principal, E4 Consulting

The recent publication of new cases of pancreatitis that are occurring in patients taking Byetta (exenatide) can't be good for Amylin/Lilly. While Byetta and investigational GLP-1 analogs are still very viable therapeutics for Type 2 Diabetes, prescribers will have to reassess the risk-benefit ratio...

Astra-Zeneca and Abbott partner on promoting Crestor..should Pfizer beware? | 08-15-2008
Analysis of: Abbott signs deal to promote Crestor in U.S. | www.chicagotribune.com
Author: Joseph Bertino, Pharm.D., Independent Consultant, Bertino Consulting

-Crestor sold 2.8 billion dollars in sales in the recent year, will this partnership result in long term exponential growth? -What are the implications for Crestor with generic simvastatin and with Lipitor going generic in the next few years? -Is a combination product going to bolster Crestor sales

A Complex Personal and Societal Issue | 07-17-2008
Author: Evan Siegel, MPhil, PhD, President and Chief Executive Officer, Ground Zero Pharmaceuticals, Inc.

The issues associated with expensive therapeutics are multifaceted and involve personal, professional and societal components. Value related to medical treatment is uniquely assessed by each individual with respect to his/her financial burden, overall lifestyle and quality of life, societal role,...

The New PhRMA “Code on Interactions with Health Care Professionals”: What will it mean? | 07-17-2008
Author: Joseph Bertino, Pharm.D., Independent Consultant, Bertino Consulting

-The new code will limit all gifts and meals to healthcare professionals, thus reducing pharmaceutical representative contact time. -Medical education programs will follow guidelines established by professional education groups -The guidelines do not go far enough for sales representative-healthcare...

A Word to the Wise... | 07-08-2008
Author: Evan Siegel, MPhil, PhD, President and Chief Executive Officer, Ground Zero Pharmaceuticals, Inc.

1. Sponsors need to be "squeaky clean" with respect to their assessment of signals of toxicity in drug develpment programs. 2. This assessment should be made at the preclinical and early clinical stages of the process, irrespective of political and financial considerations. 3. The per cent of failures...

View All GLG News by members of this Study Group

GLG InstituteSM Seminars with this Study Group's Leading Experts(?)

 

Recent Seminars

Most Common Company Types:

  • Consultancy, Pharma-Focused
  • Academic Institution*
  • Consultancy, Healthcare-Focused
  • Individual/Small Consultancy
  • Healthcare Management
  • Academic Medical Center/Hospital or Clinic
  • Laboratory, Independent
  • Pharmaceuticals/Biotechnology Research Services
  • Strategic Management

Most Common Job Types:

  • President
  • Principal
  • Owner
  • Consultant
  • Professor
  • Director
  • Chief Executive Officer
  • Physician - Attending Physician
  • Managing Director
  • Teaching Assistant
  • Board Member

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-09-05T01:45:16.907